Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAlberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe‐Paganon, Filip Garbicz, Ruben Carrasco, John Hatcher, Andres Ramirez‐Gamero, Dominic Pizzarella, Amanda Kofides, María L. Guerrera, Andrew R. Branagan, Shayna R. Sarosiek, Jorge J. Castillo, Zachary R. Hunter, Steven P. Treon
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment‐naïve patients
10.1053/j.seminhematol.2023.03.005 · 2023
CD19‐directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
10.1136/jitc-2021-004128 · 2022
A phase 2 trial investigating epcoritamab in patients with previously treated Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (WM‐NET3)
10.1182/blood-2024-206415 · 2024
P1097: CD20 CAR‐T therapy with MB‐106 for BTK inhibitor‐refractory Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)—single institution study
10.1097/01.hs9.0000971284.68877.ca · 2023
Plamotamab (XmAb®13676) for Ibrutinib‐ refractory CXCR4‐mutated extramedullary Waldenström macroglobulinemia
10.1080/10428194.2021.2005045 · 2022
CD19‐targeting CAR T‐cell therapy in transformed Waldenström Macroglobulinemia/lymphoplasmacytic lymphoma: a Descar‐T and US collaborative study
10.1182/blood-2023-173988 · 2023
A method for the elution of anti‐CD20 with an EDTA/glycine acid solution for accurate immunophenotyping of B lymphocytes sensitized with rituximab
10.1093/ajcp/aqab176 · 2022
Double‐hit alterations of TP53 identify ultra high‐risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1182/blood-2025-224 · 2025
The mutational footprints of cancer therapies
10.1038/s41588-019-0525-5 · 2019
Genetic and evolutionary patterns of treatment resistance in relapsed B‐cell lymphoma
10.1182/bloodadvances.2020001696 · 2020
CD20 mutations involving the rituximab epitope are rare in diffuse large B‐cell lymphomas and are not a significant cause of R‐CHOP failure
10.3324/haematol.2008.001024 · 2009
Identification of CD20 C‐terminal deletion mutations associated with loss of CD20 expression in non‐Hodgkin's lymphoma
10.1158/1078-0432.ccr-08-1403 · 2009
The epitope recognized by rituximab
10.1182/blood-2006-04-014639 · 2006
Combinability of epcoritamab CD20‐targeting T‐cell engager and CD20 antibody‐targeted therapies in B‐cell non‐Hodgkin lymphoma
10.1080/10428194.2025.2504719 · 2025
Anti‐CD20/CD3 T cell‐dependent bispecific antibody for the treatment of B cell malignancies
2015
CD20‐TCB with obinutuzumab pretreatment as next‐generation treatment of hematologic malignancies
10.1158/1078-0432.ccr-18-0455 · 2018
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B‐cell lymphomas
10.1182/blood.2023022348 · 2024
NCCN guidelines(R) insights: B‐cell lymphomas 3
2025
Effective clearance of rituximab‐resistant tumor cells by breaking the mirror‐symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20
10.1038/s41598-023-45491-8 · 2023
CD47 blockade by Hu5F9‐G4 and rituximab in non‐Hodgkin's lymphoma
10.1056/nejmoa1807315 · 2018
No additional external references are available.